1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)

Jaume Capdevila, Àlex Teulé, Carlos López, Rocio García‐Carbonero, Marta Benavent, Ana Custodio, Antonio Cubillo, Vicente Alonso, Teresa Alonso Gordoa, Alberto Carmona‐Bayonas, Guillermo Crespo, Montserrat Blanco-Codesido, Paula Jiménez‐Fonseca, A. Viúdez, Adelaida La Casta Muñoa, Isabel Sevilla, Marta Llanos, Ángel Segura, Jorge Hernando-Cubero, José Luís Manzano